Cambridge Enterprise Limited

Richard William Farndale

Willem Ouwehand

John Trowsdale

Alexander Barrow

Peter Alexander Smethurst

Specific binding members directed to human glycoprotein VI (GPVI), in particular human antibodies, may employ the antibody VH and/or VL domain of the scFv fragment herein termed 10B12 or one or more complementarity determining regions (CDRs) of the 10B12 heavy chain variable (VH) and/or light chain variable (VL) domains, especially VH CDR3 in other antibody framework regions. Antibody molecules are provided with advantageous and unexpected properties, especially ability to inhibit collagen-induced platelet aggregation and the adhesion of platelets to Collagen-Related Peptide (CRP). Domain 1 of human GPVI is a primary target for the 10B12 antibody with these properties, and the epitope includes lysine 59.

Human antibodies against human glycoprotein VI and their use

This invention relates to the finding that collagen peptides bind to the osteoclast-associated receptor (OSCAR) and stimulate the activation and/or differentiation of OSCAR expressing cells, such as osteoclasts and osteoclast precursor cells. Collagen peptides are described which may be useful in the modulation of the differentiation and/or activation of OSCAR expressing cells, for example in the treatment of bone defects and disorders characterized by altered differentiation and/or activation of OS-CAR expressing cells.

Growing community of inventors

Cambridge, United Kingdom

Richard William Farndale